Skip to main content
rounds.

Evidence digest

Uveitis & Ocular Immunology: the evidence, summarized every weekday

Peer-reviewed papers in uveitis & ocular immunology, summarized and ranked by evidence level. Top studies from PubMed and ClinicalTrials.gov. Updated every weekday at 06:00 CET. Built by physicians, for physicians.

Subscribe · €49 / year →See the methodology →

What rounds. covers in uveitis & ocular immunology

  • Anterior uveitis
  • Intermediate/posterior uveitis
  • Infectious (TB, syphilis, herpetic)
  • Behçet & VKH
  • Biologics (anti-TNF)
  • Masquerade syndromes

Landmark papers · uveitis & ocular immunology

Hand-picked by the editorial team. These are the studies that shaped current practice in uveitis & ocular immunology.

  1. Adalimumab in Patients with Active Noninfectious Uveitis.

    The New England journal of medicine · Jaffe G. et al. · Friday, January 1, 2016

  2. L2 · prospective cohort

    Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.

    Lancet · Nguyen Q. et al. · Friday, January 1, 2016

  3. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.

    Ophthalmology · Kempen J. et al. · Saturday, January 1, 2011

How papers reach the uveitis & ocular immunology brief

  1. Source. Every paper is fetched directly from PubMed and ClinicalTrials.gov. No paywalled aggregators. No editorial press releases.
  2. Grading. Each paper is assigned an evidence level from L1 (RCT or meta-analysis) to L5 (editorial). Bias risk is flagged separately. Both labels are visible on every card.
  3. Summarization. A 5-gate validator stack checks every summary for source faithfulness, numeric accuracy, drug-safety language, unsupported claims, and clinical-decision overreach. Anything that fails a gate is blocked, not silently weakened.
  4. Delivery. Ten papers. Twelve minutes. Every weekday at 06:00 CET. Subscribers can rate any paper as off-topic and it drops out of their feed.

The full pipeline, validators, and the founder's editorial overrides are documented on the methodology page.

Frequently asked

How do I keep up with new uveitis & ocular immunology research?
rounds. reads the new uveitis & ocular immunology literature from PubMed and ClinicalTrials.gov every weekday, grades each paper on the CEBM evidence hierarchy, and delivers the few that change practice as a twelve-minute morning brief. Every summary is checked claim by claim against the source paper.
What are the landmark uveitis & ocular immunology trials?
The studies that shaped current uveitis & ocular immunology practice are listed above under “Landmark papers”, each linked to a structured summary with its evidence level, effect size, and bias signals.
Is rounds. free?
The morning scan is free. Pro (€49 / year) unlocks the full ten-paper daily brief, the full read on every paper, and the 06:00 CET email, Monday to Friday.

Other subspecialties